Filtered By:
Cancer: HER2
Drug: Folic Acid
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
Sci Rep. 2022 Oct 14;12(1):17208. doi: 10.1038/s41598-022-21601-w.ABSTRACTTriple-negative breast cancer (TNBC) does not respond to HER2-targeted and hormone-based medicines. Epidermal growth factor receptor 1 (EGFR1) is commonly overexpressed in up to 70% of TNBC cases, so targeting cancer cells via this receptor could emerge as a favored modality for TNBC therapy due to its target specificity. The development of mesoporous silica nanoparticles (MSNs) as carriers for siRNAs remains a rapidly growing area of research. For this purpose, a multi-functionalized KIT-6 containing the guanidinium ionic liquid (GuIL), PEI and PEGy...
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Javad Parnian Leila Ma'mani Mohamad Reza Bakhtiari Maliheh Safavi Source Type: research
